ArticleDiscover oncology2026
Cell-specific multi-target mechanisms of cotinine in cervical cancer oncogenesis and progression.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCervical cancer is the fourth most common malignant tumor in women globally, with tobacco smoke being a major environmental risk factor. The tobacco-specific metabolite cotinine may promote cancer progression through mechanisms such as chronic inflammation and genomic instability, but its precise molecular targets and interactions remain unclear.
methodsWe integrated network toxicology and multi-omics for target prediction, validated by molecular biology experiments and dynamic simulations. The workflow included database screening of cotinine-related targets, identification of key modules via single-cell analysis and hdWGCNA, integration of differential gene analysis to obtain potential targets, determination of core targets using protein-protein interaction networks, pathway enrichment and machine learning, transcriptomic profiling of cotinine-induced cell type-specific pathway regulation in H8 and HeLa cells, and further validation through molecular docking, molecular dynamics simulations, and in silico knockout.
resultsInitial screening identified 151 cotinine-related targets, refined to 17 key candidates via integrated multi-omics analysis and machine learning. Molecular studies revealed multi-level carcinogenic mechanisms: in H8 cells, cotinine promoted tumorigenesis via chronic inflammation, differentiation defects, ECM remodeling, and signaling dysregulation; in HeLa cells, it accelerated progression/metastasis through dysregulated proliferation, matrix degradation, impaired metal ion transport, and cytokine storms. Validated targets-KAT2B (in H8 cells) and CA9, CCNB1, LAGE3 (in HeLa cells)-were significantly downregulated in cervical tumors. Molecular docking and dynamics simulations confirmed stable cotinine-target binding.
conclusionThis study systematically demonstrates that cotinine exerts its carcinogenic effects by targeting KAT2B, CA9, CCNB1, and LAGE3, thereby dysregulating multiple signaling pathways to induce tumorigenesis in epithelial cells and accelerate progression/metastasis in malignant cells. Elucidation of this multi-target toxicity mechanism provides a critical theoretical foundation for developing targeted detoxification strategies against tobacco-associated cervical cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.